No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
6-K: Financial Report for the Period 1 January 2025 to 31 March 2025
Novo Nordisk Cuts 2025 Outlook. But Why Are Its Shares Rising?
Novo Nordisk Says Oral Version of Wegovy Accepted for FDA Review
Cigna to Launch Specialized GLP-1 Pharmacy Next Month
CVS Health Picks Novo's Wegovy Ahead of Lilly's Zepbound
Eli Lilly Slips After Lowering Earnings Outlook